Clinical Scorecard: Clinical Characteristics and Outcomes of Invasive Pulmonary Aspergillosis in Patients with Influenza Compared to COVID-19: A Retrospective Cohort Analysis

At a Glance

Key Highlights

• CAPA patients exhibit more severe lymphopenia (reduced CD4+, CD8+ T cells, and B cells) compared to IAPA patients.
• Corticosteroid use and bacterial respiratory co-infections are more frequent in CAPA than in IAPA.
• CAPA is associated with a nearly five-fold increased risk of death within 14 days after IPA diagnosis compared to IAPA.

Guideline-Based Recommendations

Diagnosis

• Use PCR testing to confirm influenza A/B or SARS-CoV-2 infection.
• Diagnose IPA based on EORTC/MSG criteria including clinical, radiological, and mycological evidence.
• Monitor lymphocyte subsets to assess immune status.

Management

• Early therapeutic intervention is critical, especially in CAPA patients due to higher early mortality risk.
• Consider cautious use and monitoring of corticosteroids given their association with CAPA.
• Address and treat bacterial respiratory co-infections promptly.

Monitoring & Follow-up

• Close monitoring during the first 14 days following IPA diagnosis, particularly in CAPA patients.
• Regular assessment of immune cell counts and clinical status.
• Surveillance for respiratory co-infections.

Risks

• Severe lymphopenia increases susceptibility to IPA and worsens outcomes.
• Corticosteroid therapy may increase risk and severity of CAPA.
• Bacterial co-infections complicate clinical course and increase mortality risk.

Patient & Prescribing Data

Hospitalized patients with influenza or COVID-19 complicated by invasive pulmonary aspergillosis

Higher corticosteroid use in CAPA patients correlates with increased early mortality; early antifungal and supportive therapies are essential to improve outcomes.

Clinical Best Practices

• Implement early and aggressive diagnostic evaluation for IPA in patients with influenza or COVID-19 presenting with respiratory deterioration.
• Tailor immunomodulatory therapies carefully, balancing benefits and risks of corticosteroids.
• Maintain vigilance for bacterial co-infections and initiate appropriate antimicrobial therapy promptly.
• Prioritize early intervention within the first two weeks post-IPA diagnosis to reduce mortality, especially in CAPA cases.

References

• EORTC/MSG Consensus Definitions for Invasive Fungal Disease
• STROBE Statement - Strengthening the Reporting of Observational Studies in Epidemiology